Company

D.Western Therapeutics Institute

デ・ウエスタン・セラピテクス研究所

4576 · TSE · Pharmaceutical

Financials Consolidated

Revenue¥388m−17.8% year on yearConsolidated · FY12/25

Ordinary profit−¥630mConsolidated · FY12/25

Net profit−¥632mConsolidated · FY12/25

Revenue

¥414mFY12/21

¥448mFY12/22

¥428mFY12/23

¥472mFY12/24

¥388mFY12/25

Ordinary profit

−¥160mFY12/21

−¥296mFY12/22

−¥796mFY12/23

−¥1.23bnFY12/24

−¥630mFY12/25

Net profit (attributable)

−¥149mFY12/21

−¥430mFY12/22

−¥812mFY12/23

−¥1.29bnFY12/24

−¥632mFY12/25

Op. cash flow

−¥176mFY12/21

−¥355mFY12/22

−¥587mFY12/23

−¥1.30bnFY12/24

−¥494mFY12/25

Employees, whole group19 peopleFY12/25

Employees, parent company (non-consolidated)19 peopleFY12/25

Average salary¥6.67mFY12/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history

Five-year history
Fiscal year	Revenue	Ordinary profit	Net profit (attributable)	EPS	Total assets	Net assets	Op. cash flow
FY12/25	¥388m−17.8% year on year	−¥630m	−¥632m	−¥13.19	¥2.17bn	¥1,435m	−¥494m
FY12/24	¥472m+10.1% year on year	−¥1,228m	−¥1,290m	−¥36.74	¥1.67bn	¥734m	−¥1,299m
FY12/23	¥428m−4.4% year on year	−¥796m	−¥812m	−¥25.56	¥2.37bn	¥1,280m	−¥587m
FY12/22	¥448m+8.1% year on year	−¥296m	−¥430m	−¥14.50	¥2.96bn	¥1,873m	−¥355m
FY12/21	¥414m	−¥160m	−¥149m	−¥5.08	¥2.46bn	¥2,035m	−¥176m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XS4G · Japan GAAP. Each figure's years come from one report's five-year summary.